1stOncology™: Cancer Intelligence Service – Page 13877 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

West to Host Third-Quarter 2019 Conference Call

On October 10, 2019 West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, reported that it will release third-quarter 2019 financial results before the market opens on Thursday, October 24, 2019, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time (Press release, West Pharmaceutical Services, OCT 10, 2019, View Source [SID1234540922]). To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 9278868.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live broadcast of the conference call will be available at the Company’s website, www.westpharma.com, in the "Investors" section. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company’s website.

An online archive of the broadcast will be available at the West website three hours after the live call and will be available through Thursday, October 31, 2019, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International). The conference ID is 9278868.

4SC AG: Conference call to be hosted on 17 October 2019 to present the Q3 Announcement 2019

On October 10, 2019 4SC AG (4SC, FSE Prime Standard: VSC) reported that it will publish its Q3 Announcement 2019 on 17 October 2019 (Press release, 4SC, OCT 10, 2019, View Source [SID1234540921]). On this day, the Management of 4SC AG will host a conference call at 2:30 pm CEDT (8:30 am EDT) to inform about important developments in the reporting period and beyond.

Investors, financial analysts, and journalists interested in participating in the conference call can access via the telephone numbers stated below. Please join the event conference 5-10 minutes prior to the start time. You will be asked to provide the confirmation code.

Date: 17 October 2019
Time: 2:30 pm CEDT (8:30 am EDT)
Phone Numbers: +49 (0)32 22109 8334 (Germany)
+44 (0)20 3936 2999 (United Kingdom)
+1 646 664 1960 (United States)
Confirmation Code: 304466

A presentation document supporting the conference call will be available on 17 October 2019, at 4SC’s website. After the event, a replay can be accessed from there as well.

Entry into a Material Agreement

On October 9, 2019, Geron Corporation ("Geron" or the "Company") reported that it entered into an office lease agreement (the "Hillsdale Lease") with Hudson Metro Center LLC (the "Landlord"), with respect to office space within the premises located at 919 East Hillsdale Boulevard, Foster City, California (the "Hillsdale Office") (Filing, 8-K, Geron, OCT 9, 2019, View Source [SID1234542251]). The purpose of the Hillsdale Lease is to replace the Company’s current leased premises at 149 Commonwealth Drive, Suite 2070, Menlo Park, California. The initial term of the Hillsdale Lease for the Hillsdale Office is 87 months, with an option by Geron to extend for an additional five years. Also, in connection with the Hillsdale Lease, Geron has provided a security deposit to the Landlord of $310,662.

Geron has not yet occupied the Hillsdale Office as it is being prepared for the Company’s use. The Hillsdale Lease term commences upon the earlier of the date of completion of construction, which is expected to occur by March 1, 2020, or the date upon which the Company first conducts business in the Hillsdale Office. Upon the commencement of the Hillsdale Lease, the aggregate minimum future lease payments for the initial lease term is approximately $4.4 million, net of a three-month rent abatement period, and subject to scheduled annual increases. In addition, the Company is responsible for paying its pro-rata share of certain building operating expenses and taxes throughout the term of the lease.

If the Hillsdale Lease does not commence on or before August 1, 2020, Geron may terminate the Hillsdale Lease without penalty and any prepaid monthly rent payments and any undrawn security deposit will be returned by the Landlord to Geron.

The foregoing description of the Hillsdale Lease is not complete and is qualified in its entirety by reference to the full text of the Hillsdale Lease, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference

On October 9, 2019 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that results from the single agent dose-escalation portion of the ongoing Phase 1 study of AG-270 in patients with MTAP-deleted tumors and the pre-clinical translational research supporting combination strategies have been accepted for presentation at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held October 26 – 30, 2019 in Boston (Press release, Agios Pharmaceuticals, OCT 9, 2019, View Source [SID1234540953]). AG-270 is an investigational, first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor.

The schedule for the presentations is as follows:

Title: A Phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
Oral Date & Time: Sunday, October 27, 2019, 11:50 a.m. – 12:20 p.m. ET
Oral Session: Spotlight on Proffered Papers 1
Oral Location: Level 3, Ballroom AB
Poster Date & Time: Monday, October 28, 2019, 12:30 p.m. – 4:00 p.m. ET
Poster Session: Poster Session B: New Molecular Targets
Poster Location: Level 2, Hall D
Abstract: B116
Presenter: Rebecca Suk Heist, M.D., Massachusetts General Hospital

Title: Mitotic defects induced by MAT2A inhibitors guides translational drug combination strategies with AG-270 and taxanes
Poster Date & Time: Monday, October 28, 2019, 12:30 p.m. – 4:00 p.m. ET
Poster Session: Poster Session B: New Molecular Targets
Poster Location: Level 2, Hall D
Abstract: B115
Presenter: Peter Kalev, Ph.D., Agios Pharmaceuticals

Conference Call Information
Agios will host an investor event on October 27, 2019 at 6:30 p.m. ET in Boston to review the AG-270 Phase 1 dose-escalation data and pre-clinical research. The event will be webcast live and can be accessed under "Events & Presentations" in the Investors and Media section of the company’s website at www.agios.com. The archived webcast will be available on the company’s website beginning approximately two hours after the event.

GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

On October 9, 2019 GE Healthcare and Theragnostics reported that have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent (Press release, Theragnostics, OCT 9, 2019, View Source [SID1234540952]). Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations and as and when approval is received, all subsequent commercial and distribution activities.

Today, prostate cancer is the fourth largest cancer type accounting for just over 1.2 million new cases and over 350,000 fatalities around the globe in 2018. The diagnostic workflow for detecting prostate cancer starts through a blood test or biopsy, after which patients are typically referred for PET/CT imaging so that radiologists can see their tumor, lymph nodes and any metastasis in order to decide the appropriate course of treatment. The ‘heatmap’ style image enabled by the new tracer shows the precise location and intensity of PSMA, which is expressed on the surface of prostate cancer cells.

Theragnostics has reported data from a phase two clinical study which met its primary and secondary endpoints, demonstrating that one third of newly diagnosed prostate cancer patients – and over 50% of patients with biochemically recurrent disease – had their treatment plans modified as a result of a GalliProst scan. The change in patient management increased to 75% in a post-radical radiotherapy setting.

"We are excited to partner with Theragnostics on GalliProst to give vital insights into prostate cancer," said Sanka Thiru, Global Product Leader, Molecular Imaging Oncology in GE Healthcare’s Pharmaceutical Diagnostics business. "We believe that this partnership enables both parties to leverage each other’s key areas of expertise in order to accelerate the development of GalliProst and ultimately improve patient care."

Greg Mullen, CEO of Theragnostics added "This agreement is validation of the potential for our novel prostate cancer Gallium-68 (68Ga) diagnostic tracer, GalliProst which can benefit the treatment of prostate cancer patients around the globe. We are very pleased to sign our second agreement with GE Healthcare following our agreement last year for a diagnostic tracer for imaging kidney function and scarring."

Both GE Healthcare and Theragnostics will be attending the upcoming European Association of Nuclear Medicine 2019 Congress (EANM) in Barcelona Saturday October 12-16.